Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $64.9 million.

  • Kymera Therapeutics' Shares Outstanding (Weighted Average) rose 10.39% to $71.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.5 million, marking a year-over-year increase of 10.39%. This contributed to the annual value of $64.9 million for FY2024, which is 6.27% up from last year.
  • According to the latest figures from FY2024, Kymera Therapeutics' Shares Outstanding (Weighted Average) is $64.9 million, which was up 6.27% from $61.1 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Shares Outstanding (Weighted Average) registered a high of $64.9 million during FY2024, and its lowest value of $44.5 million during FY2020.
  • In the last 3 years, Kymera Therapeutics' Shares Outstanding (Weighted Average) had a median value of $61.1 million in 2023 and averaged $60.4 million.
  • Data for Kymera Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 15.58% (in 2021) over the last 5 years.
  • Kymera Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $44.5 million in 2020, then grew by 15.58% to $51.4 million in 2021, then rose by 7.39% to $55.2 million in 2022, then climbed by 10.74% to $61.1 million in 2023, then grew by 6.27% to $64.9 million in 2024.